Skip to main content
Erschienen in: Pathology & Oncology Research 2/2020

11.03.2019 | Original Article

YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells

verfasst von: Filiz Kisaayak Collak, Ummuhan Demir, Fatma Sagir

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The Yes Associated Protein 1 (YAP1) is a transcriptional cofactor negatively regulated by Hippo Pathway. The dysregulation of the pathway has been shown to have a role in tumorigenesis and metastasis in several cancers including prostate cancer (PCa). In this study, YAP1 expression was upregulated in the whole cell lysates and cytoplasmic/nuclear extracts of AR negative (PC3) compared to AR positive (LNCaP) prostate cancer cell lines and primary prostate epithelial cells (PrePEC). pYAP1 expression elevated in LNCaP compared to PC3 and PrePEC in whole cell lysates and cytoplasmic extracts. The treatment of LNCaP and PC3 with YAP1-targeting siRNA oligonucleotides (YAP1 siRNA) significantly reduced their proliferation in vitro. Furthermore, treatment with YAP1 siRNA diminished the clonogenicity, anchorage-independent growth on soft agar, migration and invasion of PC3 cells. Co-IP/WB experiments revealed that YAP1 and AR formed a complex and ChIP/PCR results confirmed that YAP1 was bound to androgen response elements (ARE) core region of the prostate specific antigen (PSA) promoter. The loss of function experiments in LNCaP and PC3 revealed that YAP1 regulates proliferation, colony formation as well as anchorage-independent growth and potentially plays an important role in migration and invasion. Finally, analysis of publicly available data sets indicated that LNCaP had no YAP1 copy number alteration whereas PC3 had gain of YAP1 which was also reflected as an increase in the mRNA level. Moreover, YAP1 copy number gain and elevated YAP1 mRNA expression were detected in clinical samples analyzed in publicly available data sets. Taken together, these results suggested that YAP1 has a role in PCa tumorigenesis.
Literatur
1.
Zurück zum Zitat Harvey KF, Pfleger CM, Hariharan IK (2003) The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 114:457–467CrossRef Harvey KF, Pfleger CM, Hariharan IK (2003) The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 114:457–467CrossRef
2.
Zurück zum Zitat Mahoney JE, Mori M, Szymaniak AD, Varelas X, Cardoso W (2014) The hippo pathway effector yap controls patterning and differentiation of airway epithelial progenitors. Dev Cell 30:137–150CrossRef Mahoney JE, Mori M, Szymaniak AD, Varelas X, Cardoso W (2014) The hippo pathway effector yap controls patterning and differentiation of airway epithelial progenitors. Dev Cell 30:137–150CrossRef
3.
Zurück zum Zitat Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. 2007;2747–61 Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. 2007;2747–61
4.
Zurück zum Zitat Ehmer U, Sage J (2016) Control of proliferation and Cancer growth by the hippo signaling pathway. Mol Cancer Res 14:127–140CrossRef Ehmer U, Sage J (2016) Control of proliferation and Cancer growth by the hippo signaling pathway. Mol Cancer Res 14:127–140CrossRef
5.
Zurück zum Zitat Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971CrossRef Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971CrossRef
6.
Zurück zum Zitat Alarcon C, Zaromytidou A-I, Xi Q, Gao S, Yu J, Fujisawa S et al (2009) Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF- pathways. Cell. 139:757–769CrossRef Alarcon C, Zaromytidou A-I, Xi Q, Gao S, Yu J, Fujisawa S et al (2009) Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF- pathways. Cell. 139:757–769CrossRef
7.
Zurück zum Zitat Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G (2001) Physical interaction with yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164–15173CrossRef Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G (2001) Physical interaction with yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164–15173CrossRef
8.
Zurück zum Zitat Haskins JW, Nguyen DX, Stern DF (2014) Neuregulin 1-activated ERBB4 interacts with YAP to induce hippo pathway target genes and promote cell migration. Sci Signal 7:ra116CrossRef Haskins JW, Nguyen DX, Stern DF (2014) Neuregulin 1-activated ERBB4 interacts with YAP to induce hippo pathway target genes and promote cell migration. Sci Signal 7:ra116CrossRef
9.
Zurück zum Zitat Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016) Prostate cancer. Lancet. 387:70–82CrossRef Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016) Prostate cancer. Lancet. 387:70–82CrossRef
10.
Zurück zum Zitat Disibio G, French SW (2008) Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 132:931–939PubMed Disibio G, French SW (2008) Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 132:931–939PubMed
11.
Zurück zum Zitat Schrecengost R, Knudsen KE (2013) Molecular pathogenesis and progression of prostate Cancer. Semin Oncol 40:244–258CrossRef Schrecengost R, Knudsen KE (2013) Molecular pathogenesis and progression of prostate Cancer. Semin Oncol 40:244–258CrossRef
12.
Zurück zum Zitat Hu X, Jia Y, Yu J, Chen J, Fu Q (2015) Loss of YAP protein in prostate cancer is associated with Gleason score increase. Tumori. 101:189–193CrossRef Hu X, Jia Y, Yu J, Chen J, Fu Q (2015) Loss of YAP protein in prostate cancer is associated with Gleason score increase. Tumori. 101:189–193CrossRef
13.
Zurück zum Zitat Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ, Basu S (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15:1752–1759CrossRef Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ, Basu S (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15:1752–1759CrossRef
14.
Zurück zum Zitat Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101:1279–1285CrossRef Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101:1279–1285CrossRef
15.
Zurück zum Zitat Xu MZ, Yao T-J, Lee NPY, Ng IOL, Chan Y-T, Zender L, Lowe SW, Poon RTP, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585CrossRef Xu MZ, Yao T-J, Lee NPY, Ng IOL, Chan Y-T, Zender L, Lowe SW, Poon RTP, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585CrossRef
16.
Zurück zum Zitat Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S (2010) Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res 70:8517–8525CrossRef Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S (2010) Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res 70:8517–8525CrossRef
17.
Zurück zum Zitat Zhang C, Liang K, Zhou G, Zhang Q, Li J (2014) Expression of hippo pathway in colorectal cancer. Saudi J Gastroenterol 20:188CrossRef Zhang C, Liang K, Zhou G, Zhang Q, Li J (2014) Expression of hippo pathway in colorectal cancer. Saudi J Gastroenterol 20:188CrossRef
18.
Zurück zum Zitat Zhou G-X, Li X-Y, Zhang Q, Zhao K, Zhang C-P, Xue C-H, Yang K, Tian ZB (2013) Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev 14:5199–5205CrossRef Zhou G-X, Li X-Y, Zhang Q, Zhao K, Zhang C-P, Xue C-H, Yang K, Tian ZB (2013) Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev 14:5199–5205CrossRef
19.
Zurück zum Zitat Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan K-H, Li X, Zhou HM, Bhowmick NA Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. Ramqvist T, editor. PLoS One 2011;6:e27529 Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan K-H, Li X, Zhou HM, Bhowmick NA Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. Ramqvist T, editor. PLoS One 2011;6:e27529
20.
Zurück zum Zitat Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H et al (2015) YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 6:17206–17220CrossRef Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H et al (2015) YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 6:17206–17220CrossRef
21.
Zurück zum Zitat Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio Cancer genomics portal: an open platform for exploring multidimensional Cancer genomics data. Cancer Discov 2(5):401–404CrossRef Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio Cancer genomics portal: an open platform for exploring multidimensional Cancer genomics data. Cancer Discov 2(5):401–404CrossRef
22.
Zurück zum Zitat Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1CrossRef Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1CrossRef
23.
Zurück zum Zitat Bao Y, Hata Y, Ikeda M, Withanage K (2011) Mammalian hippo pathway: from development to cancer and beyond. J Biochem 149:361–379CrossRef Bao Y, Hata Y, Ikeda M, Withanage K (2011) Mammalian hippo pathway: from development to cancer and beyond. J Biochem 149:361–379CrossRef
24.
Zurück zum Zitat Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM et al (2015) The hippo pathway effector YAP regulates motility , invasion , and castration-resistant growth of. Prostate Cancer Cells 35:1350–1362 Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM et al (2015) The hippo pathway effector YAP regulates motility , invasion , and castration-resistant growth of. Prostate Cancer Cells 35:1350–1362
25.
Zurück zum Zitat Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B (2015) YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun 6:8126CrossRef Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B (2015) YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun 6:8126CrossRef
26.
Zurück zum Zitat Sheng X, Bin LW, Wang DL, Chen KH, Cao JJ, Luo Z et al (2015) YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells. Mol Med Rep 12:4867–4876CrossRef Sheng X, Bin LW, Wang DL, Chen KH, Cao JJ, Luo Z et al (2015) YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells. Mol Med Rep 12:4867–4876CrossRef
27.
Zurück zum Zitat Gu S, Chen K, Yin M, Wu Z, Wu Y (2016) Proteomic profiling of isogenic primary and metastatic medulloblastoma cell lines reveals differential expression of key metastatic factors. J Proteome 160:55–63CrossRef Gu S, Chen K, Yin M, Wu Z, Wu Y (2016) Proteomic profiling of isogenic primary and metastatic medulloblastoma cell lines reveals differential expression of key metastatic factors. J Proteome 160:55–63CrossRef
28.
Zurück zum Zitat Lee HJ, Diaz MF, Price KM, Ozuna JA, Zhang S, Sevick-muraca EM, et al. Fluid shear stress activates YAP1 to promote cancer cell motility. 2017; 8:14122 Lee HJ, Diaz MF, Price KM, Ozuna JA, Zhang S, Sevick-muraca EM, et al. Fluid shear stress activates YAP1 to promote cancer cell motility. 2017; 8:14122
29.
Zurück zum Zitat Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK (2017) Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8:310CrossRef Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK (2017) Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8:310CrossRef
30.
Zurück zum Zitat Chai J, Xu S, Guo F (2017) TEAD1 mediates the oncogenic activities of hippo-YAP1 signaling in osteosarcoma. Biochem Biophys Res Commun 488:297–302CrossRef Chai J, Xu S, Guo F (2017) TEAD1 mediates the oncogenic activities of hippo-YAP1 signaling in osteosarcoma. Biochem Biophys Res Commun 488:297–302CrossRef
31.
Zurück zum Zitat Grannas K, Arngården L, Lönn P, Mazurkiewicz M, Blokzijl A, Zieba A et al (2015) Crosstalk between hippo and TGFβ: subcellular localization of YAP/TAZ/Smad complexes. J Mol Biol 427:3407–3415CrossRef Grannas K, Arngården L, Lönn P, Mazurkiewicz M, Blokzijl A, Zieba A et al (2015) Crosstalk between hippo and TGFβ: subcellular localization of YAP/TAZ/Smad complexes. J Mol Biol 427:3407–3415CrossRef
32.
Zurück zum Zitat Ferrigno O, Lallemand F, Verrecchia F, L’Hoste S, Camonis J, Atfi A et al (2002) Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene 21:4879–4884CrossRef Ferrigno O, Lallemand F, Verrecchia F, L’Hoste S, Camonis J, Atfi A et al (2002) Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene 21:4879–4884CrossRef
33.
Zurück zum Zitat Vitolo MI, Anglin IE, Mahoney WM, Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A (2007) The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol Ther 6:856–863CrossRef Vitolo MI, Anglin IE, Mahoney WM, Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A (2007) The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol Ther 6:856–863CrossRef
34.
Zurück zum Zitat Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, Frati L et al (2004) Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 294:469–479CrossRef Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, Frati L et al (2004) Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 294:469–479CrossRef
35.
Zurück zum Zitat Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT (2017) Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles. Oncotarget 8:3724–3745CrossRef Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT (2017) Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles. Oncotarget 8:3724–3745CrossRef
36.
Zurück zum Zitat Shiota M, Yokomizo A, Fujimoto N, Naito S (2011) Androgen receptor cofactors in prostate Cancer: potential therapeutic targets of castration-resistant prostate Cancer. Curr Cancer Drug Targets 11:870–881CrossRef Shiota M, Yokomizo A, Fujimoto N, Naito S (2011) Androgen receptor cofactors in prostate Cancer: potential therapeutic targets of castration-resistant prostate Cancer. Curr Cancer Drug Targets 11:870–881CrossRef
37.
Zurück zum Zitat Nguyen, Liem T.l. Nguyen LT, Tretiakova MS, Silvis MR et al. EA the YTP and I the D of A-RPTCC 2015;27(6):797–808. doi:10. 1016/j. ccell. 2015. 05. 005. Nguyen, Liem T.l. Nguyen LT, Tretiakova MS, Silvis MR et al. EA the YTP and I the D of A-RPTCC 2015;27(6):797–808. doi:10. 1016/j. ccell. 2015. 05. 005.
38.
Zurück zum Zitat Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I et al (2015) ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. Cancer Cell 27:797–808CrossRef Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I et al (2015) ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. Cancer Cell 27:797–808CrossRef
39.
Zurück zum Zitat Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP, Brabletz T ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun ; 2016;7:10498 Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP, Brabletz T ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun ; 2016;7:10498
Metadaten
Titel
YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells
verfasst von
Filiz Kisaayak Collak
Ummuhan Demir
Fatma Sagir
Publikationsdatum
11.03.2019
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00634-z

Weitere Artikel der Ausgabe 2/2020

Pathology & Oncology Research 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.